Published in Clin Interv Aging on January 01, 2008
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 19.43
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 19.28
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA (2005) 12.00
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 9.91
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Lifetime risk of developing coronary heart disease. Lancet (1999) 7.54
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care (2004) 6.68
Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA (2002) 6.30
Statins and cancer risk: a meta-analysis. JAMA (2006) 6.28
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol (2007) 4.93
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med (2005) 4.64
Deaths: final data for 2004. Natl Vital Stat Rep (2007) 3.73
Statin safety: a systematic review. Am J Cardiol (2006) 3.14
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med (2007) 3.13
Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J (2005) 2.94
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation (2007) 2.82
A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess (2007) 2.62
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation (2001) 2.60
Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) Circulation (1997) 2.34
Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA (1990) 2.32
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med (1998) 2.22
World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation (2002) 2.02
Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med (2004) 1.99
Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci (2007) 1.97
Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med (2001) 1.97
Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med (1993) 1.93
Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study. BMJ (1991) 1.79
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet (2005) 1.75
Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs (1997) 1.68
Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation (2001) 1.53
Cardiovascular risk factors in the elderly. Am J Cardiol (1989) 1.52
Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Syst Pharm (1999) 1.44
Pharmacokinetics in older persons. Am J Geriatr Pharmacother (2004) 1.35
Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation (2001) 1.34
Effects of lovastatin on cognitive function and psychological well-being. Am J Med (2000) 1.32
The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J (1998) 1.31
Age and gender bias in statin trials. QJM (2001) 1.21
Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol (2001) 1.16
Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther (2003) 1.14
Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther (2002) 1.13
Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res (1996) 1.10
Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol (2005) 1.07
Influence of statin use on endothelial function: from bench to clinics. Curr Pharm Des (2007) 0.99
Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol (2000) 0.98
Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res (1996) 0.96
High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med (1990) 0.95
Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation (1996) 0.94
Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. CNS Drugs (2004) 0.94
Cost-effectiveness of statins. Am J Cardiol (1998) 0.94
Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J (2002) 0.93
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis (2002) 0.92
Statin use after acute myocardial infarction: a nationwide study in Denmark. Br J Clin Pharmacol (2005) 0.91
Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia. Acta Diabetol (2006) 0.89
Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J (2006) 0.88
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care (2006) 0.88
Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm (2005) 0.88
Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis (2002) 0.86
Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: Results from the ELIAGE and ELICOEUR surveys. Int J Cardiol (2005) 0.84
Underutilization of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home. J Gerontol A Biol Sci Med Sci (2002) 0.84
Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study. J Intern Med (1999) 0.83
Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia. J Med Assoc Thai (2002) 0.81
Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am J Cardiol (2007) 0.80
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). Am J Cardiol (2005) 0.79
Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. Am Heart J (2006) 0.78
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med (2007) 3.13
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol (2005) 1.43
LC-MS-based method for the qualitative and quantitative analysis of complex lipid mixtures. J Lipid Res (2006) 1.42
Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation (2005) 1.34
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler Thromb Vasc Biol (2006) 1.13
Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation (2015) 1.08
Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism (2004) 1.01
Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler Thromb Vasc Biol (2004) 0.96
The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism (2005) 0.95
Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women. Arterioscler Thromb Vasc Biol (2005) 0.92
TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status. Arterioscler Thromb Vasc Biol (2005) 0.91
Effect of soy nuts on adhesion molecules and markers of inflammation in hypertensive and normotensive postmenopausal women. Am J Cardiol (2008) 0.91
Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis (2002) 0.88
Influence of the DASH diet and other low-fat, high-carbohydrate diets on blood pressure. Curr Atheroscler Rep (2005) 0.88
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism. J Lipid Res (2007) 0.86
Treating to target: implementing an effective diabetes care paradigm for managed care. Am J Manag Care (2010) 0.84
Effects of Therapeutic Lifestyle Change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects. J Lipid Res (2012) 0.79
Comparison of coronary plaque subtypes in male and female patients using 320-row MDCTA. Atherosclerosis (2012) 0.77
Lipoprotein metabolism in subjects with hepatic lipase deficiency. Metabolism (2004) 0.76
Stable isotopes in obesity research. Mass Spectrom Rev (2005) 0.75
Complete resolution of a mitral valve vegetation with anticoagulation in seronegative antiphospholipid syndrome. Clin Rheumatol (2008) 0.75